Cargando…
FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
Fibroblast growth factor (FGF) family members are mostly secreted as signaling proteins with diverse functions in development and metabolism. FGF21 is a unique FGF with metabolic, but not proliferative activities. FGF21 is mostly induced by different kinds of stress and acts though FGF receptor 1c w...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083219/ https://www.ncbi.nlm.nih.gov/pubmed/25071723 http://dx.doi.org/10.3389/fendo.2014.00107 |
_version_ | 1782324344484003840 |
---|---|
author | Itoh, Nobuyuki |
author_facet | Itoh, Nobuyuki |
author_sort | Itoh, Nobuyuki |
collection | PubMed |
description | Fibroblast growth factor (FGF) family members are mostly secreted as signaling proteins with diverse functions in development and metabolism. FGF21 is a unique FGF with metabolic, but not proliferative activities. FGF21 is mostly induced by different kinds of stress and acts though FGF receptor 1c with β-Klotho as a cofactor in an endocrine or, in parts, autocrine/paracrine manner. Hepatic FGF21 directly acts on white adipocytes to inhibit lipolysis and acts through the brain to increase systemic glucocorticoid levels and suppress physical activity in response to starvation. It also protects against dioxin toxicity. Adipocytic FGF21 induces the browning of white adipose tissue (WAT) and activates brown adipocytes in response to cold exposure. It also acts as an upstream effector of adiponectin in white adipocytes. Myocytic FGF21 protects against diet-induced obesity and insulin resistance, induces the browning of WAT, and protects against cardiac hypertrophy. In addition, Fgf21 polymorphisms are possibly related with metabolic diseases and FGF21 are biomarker of metabolic diseases. These findings indicate that FGF21 plays roles as a hepatokine, adipokine, and myokine in metabolism, injury protection, and diseases. |
format | Online Article Text |
id | pubmed-4083219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-40832192014-07-28 FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases Itoh, Nobuyuki Front Endocrinol (Lausanne) Endocrinology Fibroblast growth factor (FGF) family members are mostly secreted as signaling proteins with diverse functions in development and metabolism. FGF21 is a unique FGF with metabolic, but not proliferative activities. FGF21 is mostly induced by different kinds of stress and acts though FGF receptor 1c with β-Klotho as a cofactor in an endocrine or, in parts, autocrine/paracrine manner. Hepatic FGF21 directly acts on white adipocytes to inhibit lipolysis and acts through the brain to increase systemic glucocorticoid levels and suppress physical activity in response to starvation. It also protects against dioxin toxicity. Adipocytic FGF21 induces the browning of white adipose tissue (WAT) and activates brown adipocytes in response to cold exposure. It also acts as an upstream effector of adiponectin in white adipocytes. Myocytic FGF21 protects against diet-induced obesity and insulin resistance, induces the browning of WAT, and protects against cardiac hypertrophy. In addition, Fgf21 polymorphisms are possibly related with metabolic diseases and FGF21 are biomarker of metabolic diseases. These findings indicate that FGF21 plays roles as a hepatokine, adipokine, and myokine in metabolism, injury protection, and diseases. Frontiers Media S.A. 2014-07-07 /pmc/articles/PMC4083219/ /pubmed/25071723 http://dx.doi.org/10.3389/fendo.2014.00107 Text en Copyright © 2014 Itoh. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Itoh, Nobuyuki FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases |
title | FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases |
title_full | FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases |
title_fullStr | FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases |
title_full_unstemmed | FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases |
title_short | FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases |
title_sort | fgf21 as a hepatokine, adipokine, and myokine in metabolism and diseases |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083219/ https://www.ncbi.nlm.nih.gov/pubmed/25071723 http://dx.doi.org/10.3389/fendo.2014.00107 |
work_keys_str_mv | AT itohnobuyuki fgf21asahepatokineadipokineandmyokineinmetabolismanddiseases |